Asian Clinical Trials (ACT), the contract research organisation (CRO) based in Hyderabad, India that recently formed a strategic alliance with Chinese counterpart VPSCRO, has stepped up its operations in the US market by opening a regional office in Raleigh, Carolina.

The CRO division of biopharmaceutical company Suven Life Sciences already has a US presence in Monmouth Junction, New Jersey. The new regional office will be headed by Dr Hameed Allaudeen, vice president of clinical research and regulatory affairs, who will be supported by Deborah Levitt Smith, executive director of business development.

Allaudeen has previously worked for Pfizer Global Research and Development, GlaxoSmithKline and the US Food and Drug Administration, while Smith’s career has included stints at US-based CRO Rho, Inc, Caramedica Pharmaceuticals, PPD and Biovail Pharmaceuticals.

Lately there have several indications of Indian CROs seeking new growth abroad as western players increasingly make their presence felt in the national market.

In July Veeda Oncology, the US-based specialist research services subsidiary launched in April by Anglo-Indian CRO Veeda Clinical Research, gained access to 50 trial sites in the US by snapping up International Oncology Network (ION) Clinical Research for an undisclosed sum. This followed Veeda Oncology’s acquisition in May of Biologie et Industrie, an oncology CRO based in Paris, France.

Last April Siro Clinpharm, which bills itself as India’s leading full-service contract research organisation, purchased Omega Mediation Group, a medium-sized CRO based in Germany and with “operational capabilities” in Greece, the Baltic States and Israel.